Around 140,000 people aged 18 to 39 years old will receive additional tailored health checks from healthcare staff, and support with diabetes management under the programme
The study also showed that the measurement of HbA1c which serves as an indicator of clinical assessment sharply drops in the late teenage years among individuals with type 1 diabetes (T1D).
Mahn Singh is the first British child to be part of a trial for a new drug, teplizumab, which blocks the immune system malfunction that destroys insulin-producing cells and causes type 1 diabetes.
The Global Diabetes Compact is a WHO-driven initiative uniting stakeholders around
goals of reducing diabetes risk and ensuring that people with diabetes have equitable
access to comprehensive, affordable care and prevention. In this report we describe
the development and scientific basis for key health metrics, coverage, and treatment
targets accompanying the Compact. We considered metrics across four domains: factors
at a structural, system, or policy level; processes of care; behaviours and biomarkers
such as glycated haemoglobin (HbA1c); and health events and outcomes; and three risk
tiers (diagnosed diabetes, high risk, or whole population), and reviewed and prioritised
them according to their health importance, modifiability, data availability, and global
inequality.